- Home
- NMS vs CTSO Comparison
NMS vs CTSO Comparison
Compare NMS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- CTSO
- Stock Information
- Founded
- NMS 1993
- CTSO 1997
- Country
- NMS United States
- CTSO United States
- Employees
- NMS N/A
- CTSO N/A
- Industry
- NMS Finance Companies
- CTSO Medical/Dental Instruments
- Sector
- NMS Finance
- CTSO Health Care
- Exchange
- NMS Nasdaq
- CTSO Nasdaq
- Market Cap
- NMS 67.0M
- CTSO 72.8M
- IPO Year
- NMS N/A
- CTSO N/A
- Fundamental
- Price
- NMS $11.27
- CTSO $0.91
- Analyst Decision
- NMS
- CTSO Buy
- Analyst Count
- NMS 0
- CTSO 2
- Target Price
- NMS N/A
- CTSO $5.50
- AVG Volume (30 Days)
- NMS 12.0K
- CTSO 379.8K
- Earning Date
- NMS 01-01-0001
- CTSO 08-07-2025
- Dividend Yield
- NMS 4.11%
- CTSO N/A
- EPS Growth
- NMS N/A
- CTSO N/A
- EPS
- NMS N/A
- CTSO N/A
- Revenue
- NMS N/A
- CTSO $36,107,520.00
- Revenue This Year
- NMS N/A
- CTSO $11.15
- Revenue Next Year
- NMS N/A
- CTSO $21.39
- P/E Ratio
- NMS N/A
- CTSO N/A
- Revenue Growth
- NMS N/A
- CTSO 20.18
- 52 Week Low
- NMS $9.21
- CTSO $0.71
- 52 Week High
- NMS $12.18
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- NMS 47.82
- CTSO 44.06
- Support Level
- NMS $11.19
- CTSO $0.83
- Resistance Level
- NMS $11.45
- CTSO $1.19
- Average True Range (ATR)
- NMS 0.11
- CTSO 0.09
- MACD
- NMS -0.01
- CTSO -0.01
- Stochastic Oscillator
- NMS 32.08
- CTSO 21.91
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.